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EXPERT REVIEWVentricular restraint therapy for heart failure: A review, summary of
state of the art, and future directionsMichael H. Kwon, MD, Marisa Cevasco, MD, MPH, Jan D. Schmitto, MD, PhD, and
Frederick Y. Chen, MD, PhD
Congestive heart failure is a leading cause of death in developed countries, and its incidence is expected to increase in
parallel with the aging population.Most current therapies for congestive heart failure lead tomodest symptom relief but
are unable to significantly improve long-term survival outcomes. Indeed, there is no effective treatment except cardiac
transplantation, which remains epidemiologically insignificant because of donor pool limitations. New strategies for
treating congestive heart failure are needed. Ventricular restraint is a promising, nontransplant surgical therapy inwhich
the overall goal is to wrap the dilated, failing heart with prosthetic material to mechanically constrain the heart at end-
diastole, prevent further remodeling, and thereby ultimately improve ventricular function, patient symptoms, and sur-
vival. In this review, the principles of cardiac restraint therapy will be discussed. An overview of 3 restraint devices,
along with their specific advantages and disadvantages, will be presented. The existing peer-reviewed literature from
both animal and human trialswill be summarizedwith an emphasis on understanding themechanismof restraint therapy
and how this knowledge can be used to optimize and improve its efficacy. (J Thorac Cardiovasc Surg 2012;144:771-7)Supplemental material is available online.
Congestive heart failure (CHF) affects approximately 6 mil-
lion Americans and is the underlying cause of death in
55,000 patients annually.1 Current therapies, including
medications and lifestyle changes, offer modest symptom
relief but are unable to significantly improve long-term sur-
vival because they do little to prevent the progressive ad-
verse remodeling of damaged myocardium in CHF.
Surgical interventions for CHF include coronary revascu-
larization, valve repair or replacement, and biventricular
pacing as appropriate. Alternative approaches, including
surgical ventricular reconstruction (Dor procedure) and re-
duction left ventriculoplasty (Batista procedure), have dem-
onstrated high mortality, minimal improvement in quality
of life and ventricular function, and no survival benefit,E1-E4
ultimately precluding their widespread clinical adoption.
The Myosplint (Myocor Inc, Maple Grove, Minn),
a transventricular girdle device that passively reduces left
ventricular (LV) diameter, has variable impact on quality
of life and unknown impact on survival.E5 Left ventricular
assist device (LVAD) therapy, used as destination therapy,
bridge to transplantation, decision, or recovery, has proven
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The Journal of Thoracic and Caresource-intensive and remains associated with driveline
infections and thromboembolism. The Anstadt cup is
a pneumatic epicardial balloon device that provides systolic
and diastolic augmentation and is known to improve cardiac
function in animal models,E10 but the external driveline re-
mains a major disadvantage. All told, current interventions
often improve symptoms but have minimal impact on long-
term outcomes except for heart transplantation, for which
the epidemiologic impact remains limited by the donor
pool. Alternative nontransplant surgical therapies for CHF
are needed.
In the 1980s,Carpentier developed cardiomyoplasty, a pro-
cedure in which the heart was wrapped with a lastissimus
dorsi muscle flap and stimulated to contract with systole.E11
Although the procedurewas effective at reducingmyocardial
oxygen consumption (mVO2), wall stress, and adverse re-
modeling,2 these benefits persisted even if the muscle flap
was not stimulated, that is, these effects remainedwith simply
a passivemuscle wrap.3 Passive prostheticwraps were there-
fore developed, and ventricular restraint therapy was born.
Given that increased LV size and attendant increases in
wall stress and mVO2 are associated with poor clinical out-
comes in CHF, the goal of restraint is to prosthetically wrap
the dilated, failing heart to mechanically limit its size,
thereby preventing and reversing the process of adverse re-
modeling while improving cardiac function and patient out-
comes. There are currently 2 ventricular restraint devices
studied in both animals and humans, including a woven tex-
tile device (CorCap; Acorn Cardiovascular Inc, St Paul,
Minn) (Figure 1)4 and a Nitinol mesh device (HeartNet;
Paracor Medical, Sunnyvale, Calif) (Figure 2).5 A polyure-
thane half-ellipsoid balloon device has been experimentally
developed by our group (Polyzen, Inc, Apex, NC) (Figures
3 and 4).6 This review will summarize the mechanisms,
clinical outcomes, and limitations of these devices, withrdiovascular Surgery c Volume 144, Number 4 771
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CHF ¼ congestive heart failure
EDD ¼ end-diastolic dimension
EDP ¼ end-diastolic pressure
EDV ¼ end-diastolic volume
EF ¼ ejection fraction
ESV ¼ end-systolic volume
FMR ¼ functional mitral regurgitation
LV ¼ left ventricular, left ventricle
LVAD ¼ left ventricular assist device
MMP ¼ matrix metalloproteinase
MR ¼ mitral regurgitation
mVO2 ¼ myocardial oxygen consumption
MVR ¼ mitral valve replacement
NYHA ¼ New York Heart Association
Ptm ¼ transmural myocardial pressure
QVR ¼ quantitative ventricular restraint
RV ¼ right ventricular, right ventricle2 The Jan emphasis on how restraint therapy can be further opti-
mized to improve efficacy.
ACORN: CORCAP
The Acorn CorCap Cardiac Support Device was the first
andmost extensively studied restraint device (Figure 1). It is
composed of a flexible, polyethylene-terephthalate mesh
that covers both ventricles, creating an absolute limit to
the end-diastolic volume (EDV). It is placed via median
sternotomy and secured with 8-10 polypropylene sutures
circumferentially around the atrioventricular groove, after
which excess mesh is excised and resewn to ensure a snug
fit at end-diastole.7 The degree of tightness is adjusted to
achieve approximately 5% reduction in the echocardio-
graphic diameter of the heart.7
Animal Studies
Hemodynamic studies. In 1999, the first reported animal
study of ventricular restraint demonstrated that prophylactic
ventricular restraint is sufficient to attenuate the adverse
functional and morphologic changes associated with post-
infarction CHF.8 Sheep that underwent placement of a Mar-
lex (polypropylene) mesh restraint device before creation of
a delayed anteroapical infarct via coronary snare occlusion
had significantly lower LV end-diastolic pressure (EDP),
EDV, end-systolic volume (ESV), end-systolic elastance,
and strokework after 8 weeks compared with untreated con-
trols. Restraint also prevented infarct expansion while im-
proving LV sphericity, cardiac output, and ejection
fraction (EF).8 A later study of sheep with posterior infarcts
confirmed improvements in LV sphericity and reductions in
LV EDVafter 8 weeks of therapy.9ournal of Thoracic and Cardiovascular SurgSubsequent animal studies have modeled the more clini-
cally relevant scenario in which the CorCap is not placed
prophylactically, but rather after the development of ische-
mic CHF, induced by coronary microembolization in dogs
or open surgical coronary ligation in sheep. These studies
showed that 2 to 3months of CorCap treatment not only pre-
vents but also reverses the adverse changes seen in CHF, as
demonstrated by reduced LV dilatation,4,10-15 improved LV
EF,11-13 limited infarct expansion,16 preserved border zone
function,16-18 and improved LV sphericity (LV length/LV
width).14
Other benefits include decreased left atrial enlargement
and improved left atrial function,E12 as well as decreased se-
verity of subsequent ischemic functional mitral regurgita-
tion (FMR) when placed prophylactically.14,18 Restraint
can also eliminate preexisting trace-to-mild mitral regurgi-
tation (MR),10 but to date, no animal studies have demon-
strated the more clinically relevant ability to reverse more
severe grades of preexisting FMR.
Biochemical analysis. Animal studies of the CorCap have
yielded insight into the mechanism of ventricular restraint
at the cellular and molecular levels. Compared with un-
treated controls, 3 months of CorCap treatment in dogs
with CHF decreased the expression of stretch response
proteins, including p21ras, c-fos, and p38 a/b mitogen-
activated protein kinase, suggesting that restraint can in-
duce a global attenuation of the stretch response known
to cause cardiomyocyte hypertrophy and subsequent ad-
verse remodeling in CHF.E13 In addition, long-term Cor-
Cap treatment restores myocardial calcium cycling,
resulting in improved contractility attributed ultimately
to improved phosphorylation of sarcoplasmic reticulum
Ca2þATPase, a calcium pump in the sarcoplasmic reticu-
lum involved in the sequestration and release of
calcium.E14
CorCap treatment also reverses maladaptive genetic
changes associated with CHF. These effects include upregu-
lation of a-myosin heavy chain mRNA (associated with im-
proved contractility)E15 and downregulation of mRNA for
alpha and beta natriuretic peptides (high levels of which
are associated with poor outcomes in CHF).E16 CorCap
treatment also upregulates mRNA expression of vascular
endothelial growth factor and basic fibroblast growth factor,
and downregulates several index matrix metalloproteinases
(MMPs; eg, MMP-1, MMP-2, and MMP-9), normalizing
these factors in animals with CHF.15,E17,E18 Finally,
CorCap treatment leads to reversal of myocardial collagen
degradation, a maladaptive process occurring in CHF in
which both the overall collagen content and the relative
proportion of fibrillar collagen (type I) decrease.E19,E20
Together, these effects are thought to produce
myocardium that is less prone to infarct expansion and
ventricular dilation.E19,E20ery c October 2012
FIGURE 1. Acorn CorCap Cardiac Support Device (Acorn Cardiovascu-
lar Inc, St Paul, Minn). The device is attached at the atrioventricular groove
using interrupted sutures. An anterior seam is used to create the proper de-
vice fit. Reprinted with permission.19
FIGURE 3. Quantitative ventricular restraint device. Schematic of a coro-
nal section. Reprinted with permission.32
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Initial safety studies. In 1999, initial safety studies of
CorCap placement in 32 patients with New York Heart
Association (NYHA) class II and III heart failure in Ger-
many (N ¼ 27) and Australia (N ¼ 5) showed significant
improvements in NYHA classification, reduced LV size,
and no device-related morbidity.19,20 By 2002, pooled
data from 48 patients worldwide, 33 of whom received
concomitant cardiac surgery, corroborated these results,FIGURE 2. Paracor HeartNet device (Paracor Medical, Sunnyvale, Calif)
implanted over a heart model. Reprinted with permission.27
The Journal of Thoracic and Cawith no device-related intraoperative complications and
a mean implantation time of 27 minutes.19 There were 8
early and 9 late deaths, none of which were device related,
although 1 of the early deaths occurred after device place-
ment alone without concomitant cardiac surgery.19 Both
LV end-diastolic dimension (EDD) and EF improved as
early as 3 months, with further improvements at 6 and
12 months (LV EDD reduction from 72.8 to 64.1 mm,
EF increase from 23.6% to 29.9%) that were preserved
at both 2419 and 3620 months. In addition, patients treated
with the CorCap had substantial improvements in CHF
symptoms and NYHA classification.19,20
Randomized clinical trials. The Acorn Trial began in
2004 as a randomized, controlled trial of 300 patients in
29 centers in the United States and Canada to evaluate the
safety and efficacy of the CorCap in patients with CHF.21
In the nonmitral surgery stratum (107 patients), patients
with CHF without significant MR were randomized to Cor-
Cap implant versus optimal medical therapy. In the mitral
surgery stratum (193 patients), patients with CHF with
MR were randomized to mitral valve replacement (MVR)
or MVR with CorCap implantation to determine whether
CorCap implantation added incremental value to MVR.22
The primary end point of the study was a clinical composite
score based on survival, NYHA classification, and the need
for major cardiac procedures.
Twelve months postoperatively, pooled analysis of both
strata showed that CorCap treatment significantly reduced
the need for major cardiac procedures (heart transplant,
LVAD, mitral/tricuspid surgery) and improved NYHA
functional status without any differences in device- or
implantation-related deaths, serious adverse events, or hos-
pitalizations.23 However, no survival advantage (or disad-
vantage) was seen in the treatment group.23 For secondary
end points, there were significant reductions in the mean
LV EDV (>30% reduction) and LV ESV (>25% reduc-
tion), and an increase in the mean LV sphericity index
(>0.06 unit increase), but no differences in the mean LVrdiovascular Surgery c Volume 144, Number 4 773
FIGURE 4. A, Photograph of half-ellipsoidal fluid-filled balloon for
quantitative ventricular restraint (QVR). B, Intraoperative photograph of
balloon implantation. Reprinted with permission.6 LA, Left atrium; RA,
right atrium.
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exception of the effect on the EF, the Acorn Trial confirmed
nearly all of the positive effects of reverse ventricular re-
modeling and function seen in animal studies and initial
safety trials. The primary and secondary end points were
qualitatively maintained at 324 and 525 years of follow-up.
Ultimately, however, the Food and Drug Administration
did not approve the device primarily over concerns of safety
(citing the 7.8% perioperative mortality in the non-MVR
stratum) and efficacy.25 However, the lack of any survival
disadvantage at 5 years may reinvigorate interest in this
therapy clinically.25
Results from the MVR stratum were initially reported at
18 months and demonstrated an exceedingly low overall774 The Journal of Thoracic and Cardiovascular Surgoperative mortality of 1.6% at 30 days.22 Patients receiving
MVR alone demonstrated progressive and significant de-
creases in LV EDV (50 mL decrease) and LV ESV
(40 mL decrease), increases in EF (from 23.9% to
28.5%) and sphericity index (0.116 unit increase), and dra-
matic improvements in mean MR grade (from 2.66 to
0.59).22 More important, however, the CorCap plus MVR
group had further incremental improvements in LV EDV,
LV ESV, and LV sphericity.22 Five-year results demon-
strated a 75-mL reduction in the LV EDV in controls who
underwent MVR alone, with an additional 16.5-mL incre-
mental reduction in those who also received CorCap place-
ment.26 Neither the early nor late follow-up reports
demonstrated any difference in the overall survival, fre-
quency of recurrent MR, or rate of cardiac constriction.
The impact on NYHA class was not reported, and only
the earlier report describes an incremental improvement
in quality of life as assessed by the Minnesota Living
with Heart Failure Questionnaire.22
One important criticism of the entire Acorn Trial is the
inclusion of the MVR stratum. This made the overall study
somewhat difficult to understand conceptually, because re-
currence of FMR is an intimately related but different out-
come than reverse remodeling of heart failure. Further
confusing the issue is that fact that only 6% of the patients
in the MVR stratum had ischemic MR as the cause of the
MR; ischemia, of course, is the primary cause of FMR in
the general population.1,E21-E23 This criticism also applies
to the non-MVR stratum, because most patients enrolled
did not have ischemia as the primary cause. Thus, the re-
sults of the trial were criticized as being difficult to extrap-
olate to the more common ischemic general population
with CHF.
The authors concluded that their data supported CorCap
use for patients with nonischemic heart failure with moder-
ate to severe LV dysfunction and significant MR despite
medical optimization.26 In addition, the trial determined
that patients with a preoperative LV EDD between 30 and
40 mm/m2 of body surface area benefited most from the
CorCap.22 Above this level, CHF was considered too ad-
vanced to benefit from restraint; below this level, the ventri-
cle was not dilated enough to justify invasive treatment with
the CorCap.22,26 Ultimately, although CorCap placement
results in sustained improvements in indices of LV
remodeling in patients with moderate to severe largely
nonischemic CHF, there are no major differences in
survival or freedom from major cardiac events and no
clear effect on symptoms or quality of life, leaving the
overall efficacy of this specific application of ventricular
restraint somewhat guarded in its current form.
PARACOR HEARTNET
The Paracor HeartNet (Figure 2) is the only other re-
straint device that has undergone human trials. It differsery c October 2012
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highly elastic Nitinol mesh and therefore exerts continuous
elastic force on the heart throughout the cardiac cycle and
not just at end-diastole.5 Second, although CorCap implan-
tation requires median sternotomy and epicardial sutures,
the HeartNet is implanted via left mini-thoracotomy using
an introducer sheath and adheres to the heart by a textured
inner surface.5
On the basis of evidence from a single prior animal study
demonstrating the ability of the HeartNet device to attenu-
ate LV EDVand ESVwhen placed immediately after infarct
creation in sheep,5 initial clinical safety and feasibility stud-
ies were initiated and demonstrated low complication rates
in 20 patients with nonischemic heart failure (NYHA class
II and III) who received the device without other concomi-
tant cardiac procedures.27 After this, a multi-institutional,
nonrandomized, international study of 51 similar patients
demonstrated favorable safety profiles with significant re-
ductions in the LV EDD, LV EDV, and LV ESV, and signif-
icant improvements in the 6-minute walking test and the
Minnesota Living with Heart Failure Questionnaire at 6
months.28 A randomized, controlled trial (Prospective Eval-
uation of Elastic Restraint to Lessen the Effects of Heart
Failure [PEERLESS-HF]) was then conducted to compare
HeartNet treatment with optimal medical therapy in 217 pa-
tients with NYHA class III CHF on stable medical regi-
mens, LV EF 35% or less, LV EDD less than 85 mm, and
LV EDD index less than 40 mm/m2.29 Despite showing sig-
nificantly decreased LV EDD and LV ESD after 6 months of
treatment, the trial was halted when no significant differ-
ences in mVO2 at 6 months or survival at 12 months were
observed.29 No further clinical reports of the HeartNet de-
vice have since been published.
QUANTITATIVE VENTRICULAR RESTRAINT
Quantitative ventricular restraint (QVR) was developed
to better understand the mechanics of restraint and thereby
establish a means to optimize its benefits by overcoming
the major limitations of prior devices, namely, the inability
to measure and adjust the restraint level. With previous
nonquantitative devices, the fundamental hypothesis that
restraint ultimately leads to reverse remodeling by de-
creasing transmural myocardial pressure (Ptm) and thereby
mVO2 cannot be tested because epicardial pressures, re-
quired for obtaining Ptm, cannot be measured. In addition,
because surgeons are instructed to implant current devices
‘‘snugly’’ around the heart, standardized methods for ac-
curately establishing and adjusting wrap tightness do not
exist. Once implanted, the wrap remains constant even
as the heart reverse remodels and shrinks, causing the
wrap to become effectively looser and redundant. Because
the level of restraint may determine the degree of benefit
and risk to the failing heart, our group perceived the non-
adjustable and nonmeasurable nature of earlier devices asThe Journal of Thoracic and Cathe biggest limitation to developing rational criteria to op-
timize therapy in a physiologic manner.
We therefore designed a QVR device that allows for both
measurement and adjustment of the restraint level. The de-
vice itself is a flexible, inflatable, half-ellipsoidal polyure-
thane balloon that fits around both ventricles (Figures 3
and 4) and is connected to an airtight access line terminating
in a subcutaneous port in the chest (Port-a-Cath; Bard Ac-
cess Systems, Salt Lake City, Utah) through which the vol-
ume and pressure in the balloon can be adjusted and
measured transcutaneously. Because the inner layer of the
device is elastic and redundant, and the outer layer is inelas-
tic, any fluid introduced into the balloon lumen has only one
direction of filling, that is, toward the heart, thereby creating
a tighter wrap. The Ptm can be calculated using the balloon
pressure, which is, by definition, equal to the epicardial
pressure.
Animal Studies
We first determined the acute effects of varying the re-
straint level as defined by the balloon pressure at end-
diastole, with the hypothesis that there is an optimal re-
straint level that maximizes the benefit to the heart without
leading to tamponade. By using a postinfarction ovine
model of CHF, we showed that QVR at a restraint level of
3 mm Hg significantly reduced the LV Ptm and markers of
mVO2, including the tension-time index and pressure-
volume area, without causing tamponade in the acute set-
ting.6 Restraint levels of 5 and 8 mm Hg led to cardiac tam-
ponade, suggesting that 3 mm Hg was the optimal restraint
level.6 After 2 months of restraint at this optimal level, there
were significant improvements in the LV EDV (30% reduc-
tion from baseline) and the LV EF (60% improvement from
baseline, 24% higher than untreated controls).6 In addition,
when normal hearts were compared with cardiomyopathic
hearts, ventricular restraint decreased LV Ptm, tension-
time index, and pressure-volume area equally at the re-
straint levels tested, demonstrating that LV size, preload,
and contractility were not determinative factors in the re-
duction of Ptm and mVO2, that is, the mechanical effect of
restraint is determined primarily by wrap mechanics and
not by the contractile or mechanical properties of the heart
itself, thereby making standardization of QVR for patients
possible.6
We then investigated the feasibility of postoperatively
measuring and adjusting the restraint level after QVR place-
ment.30 After QVR implantation in 9 postinfarct sheep with
CHF, restraint level was measured percutaneously after 2
days and adjusted back to the optimal restraint level of 3
mm Hg. In addition to documenting improvements in LV
EDV and LV EF as early as 3 weeks postoperatively, this
study demonstrated that it is technically feasible to postop-
eratively adjust and measure the effects of varying the re-
straint level acutely in real-time.rdiovascular Surgery c Volume 144, Number 4 775
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the effects of chronic restraint at varying restraint levels
(1.5 and 3.0 mm Hg) and found that compared with the
low restraint group, the high restraint group had signifi-
cantly greater reductions in LV EDV (28% reduction vs
18% reduction) and a trend toward greater improvements
in LV EF (28% to 44% vs 28% to 41%).31 In a second
part of the same study, we compared chronic application
of QVR at 3.0 mm Hg (with biweekly adjustment of the re-
straint level back to 3.0 mm Hg) to standard, nonquantita-
tive mesh wrap restraint and found that QVR
demonstrated significantly greater reductions in LV EDV
(12.7% vs 5.7% reduction) and LV ESV (20.6% vs
11.4% reduction), and a trend toward greater improvements
in LV EF (18.9% vs 14.4% increase).31 Of note, there were
significant decreases in the measured restraint level as early
as 2 weeks postoperatively, coincident with when LV EDV
first began to decrease. This shows that early reverse remod-
eling does make the QVR device effectively looser and un-
derscores the potential benefit of periodic readjustment to
maximize efficacy.31
Finally, we tested the hypothesis that in standard QVR, in
which a single level of restraint is applied to both ventricles,
the pressure exerted on the right ventricle (RV) and not the
LVaccounts for the tamponade effect seen at higher restraint
levels. In the LV, increases in the level of restraint up to 8mm
Hg led to beneficial decreases in Ptmwithout any effect onLV
diastolic compliance or LV EDP.32 Meanwhile, the same in-
creases in restraint led to significant decreases in RV compli-
ance and increases in RV EDP (both detrimental), but
without any reduction in the Ptm.
32 In other words, the bene-
fits of standard, biventricularQVR for left-sided heart failure
lie solely with the effect of restraint on the LV, whereas the
detrimental effects leading to tamponade lie solely with the
effect on the RV. This has led to the hypothesis currently be-
ing tested that for LV failure, applying partial restraint (ie, re-
straint of the LVonly while leaving the RV exposed) might
allow higher levels of restraint to be applied without acutely
causing tamponade, and that these higher restraint levels
might also produce even greater chronic benefits.
DISCUSSION
Ventricular restraint studies during the last 15 years have
clearly established that even nonquantitative restraint de-
vices can induce reverse remodeling in CHF. However, de-
spite encouraging clinical safety profiles, the efficacy of
these devices, although durable over a period of up to 5
years as seen in the most recent reports, remains limited.
Despite clear improvements in LV remodeling, there re-
mains no proven benefit in terms of long-term ventricular
function or survival. Furthermore, there seems to be a limit
to the amount of reverse remodeling with the CorCap and
HeartNet, neither of which are available commercially be-
cause of financial difficulties encountered after losing776 The Journal of Thoracic and Cardiovascular SurgFood and Drug Administration approval for clinical use
and investigation.
Meanwhile, ongoing animal studies of QVR have dem-
onstrated that both the acute and the chronic physiologic
benefits of nonquantitative restraint can be significantly im-
proved. In particular, QVR has demonstrated the fundamen-
tal principle that the ability to apply an accurately quantified
level of restraint is important, because it determines the de-
gree of acute benefit and risk to the heart. If the level of re-
straint is too high, tamponade ensues, but if the restraint
level is too low, the benefits of restraint are not fully real-
ized. As a consequence, there is an optimal restraint level
that maximizes these acute benefits without subjecting the
heart to restrictive physiology. Moreover, in addition to
these acute differences, there is a restraint level-dependent
response in the degree of remodeling and functional im-
provement in the chronic period as well,31 for which the dif-
ferences in acute hemodynamics and energetics are likely
responsible. Ultimately, candidates for optimized QVR
would likely be similar to those in the Acorn Trial, that is,
medically optimized patients who do not require LVAD
support or transplant acutely, but whose CHF is symptom-
atic and associated with LV dilation sufficient to warrant re-
straint therapy.
Avenues that merit additional investigation include
whether partial QVR for LV failure is superior to standard
(biventricular) QVR, with the goal of maximizing benefit
to the diseased LV while avoiding tamponade by leaving
the nondiseased RV unrestrained. Others include the possi-
bility that restraint can be an adjunct or alternative to mitral
surgery in the setting of FMR, a condition for which signif-
icant controversy remains concerning the optimal method
of surgical management. Finally, because most studies of
restraint have focused on LV failure, it remains unknown
whether partial RV restraint may be beneficial in the setting
of isolated RV failure. Put more generally, varying combi-
nations of RVand LV failure may warrant specific combina-
tions and levels of restraint to most optimally benefit the
heart.
CONCLUSIONS
Despite several major limitations to standard ventricular
restraint therapy in its most recent nonquantitative clinical
iteration, these limitations are largely a consequence of an
incomplete physiologic understanding of the mechanism
of restraint. As a new paradigm for ventricular restraint,
QVR provides the ability to conduct rational investigation
into the energetic and hemodynamic mechanisms that un-
derlie its clinical benefit, and thereby the potential to realize
another significant step toward optimizing ventricular re-
straint in a physiologic manner to maximize that benefit.
Additional animal studies of QVR will be necessary to re-
new interest and rationale for initiating future human clini-
cal studies of further optimized ventricular restraint. Asery c October 2012
Kwon et al Expert Reviewrestraint evolves in this manner, the hope is that there will be
an epidemiologically significant improvement in clinical
efficacy beyond what has been borne out in the currently
available studies of standard restraint.
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